ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial✰

Background: The dense stroma of pancreatic ductal adenocarcinoma (PDAC) is thought to impede tumour drug delivery. LSTA1, a novel cyclic tumour-penetrating peptide internalising arginylglycylaspartic acid, promotes tumour-specific drug delivery. In the phase Ib setting, LSTA1 3.2 mg/kg with gemcitab...

Full description

Bibliographic Details

Published in:	ESMO Gastrointestinal Oncology
Main Authors:	J. Lee, A. Dean, T. Price, K. Sjoquist, V. Gebski, J. Mumford, F. Day, S. Yip, K. Wilson, C. Jackson, S. Padinharakam, B. Lee, M. Burge, D. Siu, C. Karapetis, L. Chantrill, Z.W. Wong, R. Jennens, C. Lomma, A. Franscesconi, S. Ackland, J. Lynam, S. Wahlroos, J. So, M. Jameson, N. Tebbutt, S. Gill, D. Grimes, C. Steer, M. Harris
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Subjects:	iRGD pancreatic ductal adenocarcinoma pancreatic carcinoma LSTA1 chemotherapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949819823000018